CRVO PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

CRVO ▲ +0.33% at T+5d

NEUTRAL call ✓ call won +0.33% · α vs SPY -1.29% · entry $3.04 → $3.05

Next anchor: T+20d in 6d

Last close $2.91 (close Jun 8) · -4.28% from $3.04 entry

Entry anchored
May 18, 2026
via day open

T+1d

-4.93%

call -4.93% · α -4.28%

$2.89

settled 22d ago

T+5d

+0.33%

call +0.33% · α -1.29%

$3.05

settled 15d ago

T+20d

—

call — · α —

—

in 6d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

CervoMed reported Q1 2026 EPS of -$0.86, beating consensus of -$0.98 by 12.2%, but net loss widened to -$8.0M from -$4.9M YoY primarily due to a $1.9M decrease in grant revenue. The company plans to initiate a Phase 3 DLB trial in H2 2026 subject to financing, with cash runway only into Q3 2026, creating significant funding uncertainty for a pre-revenue biotech.

Actionable Insight

The EPS beat is overshadowed by a tightening cash runway into Q3 2026 a financing event (equity offering or partnership) is likely imminent to fund the Phase 3 DLB trial. Track any SEC filings related to capital raises or partnership announcements — these are dilutive financing would pressure the stock. The Phase 3 DLB catalyst is the key value driver but is contingent on funding.

Key Facts

Q1 2026 EPS -$0.86 vs consensus -$0.98 (12.2% beat), net loss -$8.0M vs -$4.9M YoY
Cash, cash equivalents and marketable securities declined to ~$12.9M from $20.9M at Dec 31, 2025
Cash runway only into Q3 2026, raising substantial doubt about ability to fund planned Phase 3 DLB trial without new financing
Plans to initiate Phase 3 DLB trial in H2 2026, subject to available financing — Phase 3 is the value catalyst but at risk of delay
No grant revenue recognized vs $1.9M in prior year period due to completion of RewinD-LB trial
Positive Phase 2b data and FDA alignment on Phase 3 design confirmed, with new MRI data presented at AAN 2026
Pipeline includes ongoing Phase 2a trials in nfvPPA (enrollment completed US) and RESTORE stroke recovery mid-2026 topline)

Financial Impact

Net loss $8.0M net loss in Q1 2026 cash burn rate ~$8M/quarter implies ~$32M annualized cash burn cash only $12.9M as of March 31 2026

cash and cash equivalentsnet lossgrant revenueR&D expenses

Risk Factors

Cash runway only into Q3 2026; going concern risk if financing not secured
Phase 3 DLB trial initiation at risk of delay or cancellation without adequate capital
Pre-revenue clinical-stage biotech with history of negative EPS surprises (Q2-Q4 2025 missed consensus each quarter)
Dilution risk from likely equity financing given current market cap of $32M

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

93% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3296513

7 reports for CRVO

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+5▲ +7.98%Mar 4, 2026

Filters

Reports for CRVO — sortable, filterable
	Type				Now
May 18, 2026 22d ago	8-K BEARISH ★ 6/10	$2.89 $3.04	▼ −5.19%	▼ −2.89%	$2.91 (−0.69%)
May 18, 2026 22d ago	Press Release MIXED ★ 6/10	$3.04 $3.05	▲ +0.33%	▼ −1.29%	$2.91 (−4.28%)
Apr 22, 2026 6w ago	8-K BULLISH ★ 7/10	$3.85 $3.65	▼ −5.19%	▼ −6.67%	$2.91 (−24.42%)
Apr 22, 2026 6w ago	Press Release MIXED ★ 6/10	$3.94 $3.82	▼ −2.92%	▼ −2.98%	$2.91 (−26.14%)
Apr 7, 2026 9w ago	8-K NEUTRAL ★ 4/10	$4.04 $4.04	· 0.00%	▼ −3.52%	$2.91 (−27.97%)
Mar 17, 2026 12w ago	Press Release MIXED ★ 6/10	$4.53 $3.92	▼ −13.47%	▼ −10.81%	$2.91 (−35.76%)
Mar 4, 2026 13w ago	8-K BULLISH ★ 7/10	$4.01 $4.33	▲ +7.98%	▲ +10.22%	$2.91 (−27.43%)

US Market Status

Market Closed — Opens in 7h 8m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access